On Thursday, AnaptysBio reached an important technical milestone, with its Relative Strength (RS) Rating climbing into the 80-plus percentile with an upgrade to 83, an increase from 79 the day before.
Risk Management In The Stock Market: How Much Money To Invest Now
IBD's unique RS Rating measures technical performance by using a 1 (worst) to 99 (best) score that shows how a stock's price performance over the last 52 weeks matches up against other publicly traded companies.
History reveals that the stocks that go on to make the biggest gains often have an RS Rating north of 80 in the early stages of their moves.
While it's not currently an ideal time to buy shares, see if the stock manages to form a chart pattern and break out.
The company posted 0% earnings growth in the latest quarterly report, while sales growth came in at 287%.
The company holds the No. 127 rank among its peers in the Medical-Biomed/Biotech industry group. Exelixis, TG Therapeutics and Anbio Biotechnology are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
